Abstract 756P
Background
CLDN6 is expressed at high levels in multiple cancers with little to no expression in normal tissues and has been implicated in the initiation, progression, and metastasis of some cancers. CLDN6 is an ideal target for development of new therapeutics. TORL-1-23 is first-in-class ADC targeting the tumor-specific antigen CLDN6.
Methods
This ongoing first in human study (TORL123-001, NCT05103683) characterizes the safety, tolerability, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended phase 2 dose (RP2D) of TORL-1-23 in participants with advanced solid tumors. Pharmacokinetics (PK), immunogenicity and clinical efficacy are also assessed. TORL-1-23 is administered IV every 3 weeks. In Dose Escalation, cohorts up to 6 participants are evaluated at each dose level according to an accelerated titration design. In Dose Expansion, patients with CLDN6-expressing cancers will be evaluated to confirm the RP2D in ovarian cancer, NSCLC, and other CLDN6+ cancers using an IHC companion diagnostic. Doses above the historic MTD for MMAE containing ADCs are being evaluated given the favorable safety/tolerability at doses <2.4 mg/kg.
Results
30 patients with ovarian (n=22), testicular (n=5), and endometrial (n=3) cancers were enrolled across 9 dose levels ranging from 0.2 to 3 mg/kg IV every 3 weeks (as of 01MAY2023). 93% of pts had received ≥ 3 prior lines of treatment in the metastatic setting. The most common treatment-related adverse events were Gr1/2 fatigue (n=6), anemia (n=5), and peripheral neuropathy (n=4). No DLTs were observed at doses ≤2.4 mg/kg. Sustained PK exposure of TORL-1-23 over the dosing interval and low levels of circulating MMAE are noted. Partial responses (PR) were observed in 7/22 (32%) efficacy evaluable participants with CLDN6+ disease (6 ovarian, 1 testicular) across dose levels. 3/3 (100%) participants with CLDN6+ ovarian cancer responded at the 2.4 mg/kg dose level. Data from 3 mg/kg are pending.
Conclusions
In participants with heavily-pretreated CLDN6-expressing ovarian cancer, the novel TORL-1-23 ADC has a favorable safety/tolerability profile and encouraging antitumor activity in a phase 1 dose finding study. Further evaluation in ovarian cancer and other CLDN6+ cancers is warranted.
Clinical trial identification
NCT05103683.
Editorial acknowledgement
None.
Legal entity responsible for the study
TORL Biotherapeutics.
Funding
TORL Biotherapeutics.
Disclosure
A. Machado, S. Davenport, S. Bilic, L. Miller, A. Chung: Financial Interests, Institutional, Other, Fee for Service: TORL Biotherapeutics. M.F. Press: Financial Interests, Personal, Advisory Board: Biocartis, Cepheid, Lilly USA, LLC; Financial Interests, Personal, Other, Consultant: Zymeworks, Inc., Eli Lilly & Company, AstraZeneca, Merck, Novartis; Financial Interests, Personal, Ownership Interest: TORL Biotherapeutics LLC; Financial Interests, Institutional, Other, Fee-for-Service Agreements: Zymeworks, Inc., TRIO-US, TRIO; Financial Interests, Institutional, Other, Fee-For-Service Agreements: TORL Biotherapeutics LLC; Financial Interests, Institutional, Other, Fee-for-Service Agreement: Ambrx, 1200 Pharma. S. Letrent: Financial Interests, Personal, Full or part-time Employment: TORL Biotherapeutics. D. Slamon: Financial Interests, Personal and Institutional, Leadership Role: TORL Biotherapeutics; Financial Interests, Personal and Institutional, Ownership Interest: TORL Biotherapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
800P - Response to chemotherapy following PARP inhibition in UK ovarian cancer (OC) patients
Presenter: Sarah Howlett
Session: Poster session 11
802P - Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study
Presenter: Frederik Marmé
Session: Poster session 11
803P - Pre-treatment systemic inflammatory markers predict survival in endometrial cancer cases: A Japanese gynaecologic oncology group 2043 exploratory data analysis
Presenter: Shin Nishio
Session: Poster session 11
805P - Tumor-informed ctDNA detection as a predictive marker for postoperative residual disease in epithelial ovarian cancer: A feasibility study
Presenter: Christoph Grimm
Session: Poster session 11
806P - Pilot ambulatory malignant bowel obstruction (MBO) electronic monitoring program in patients with gynecologic cancers
Presenter: Ainhoa Madariaga Urrutia
Session: Poster session 11
807P - Predicting surgical outcomes in patients with advanced ovarian cancer through MRI based preoperative evaluation
Presenter: Shujuan Liu
Session: Poster session 11
808P - Cell-free human papillomavirus (HPV) DNA is a sensitive biomarker for monitoring treatment response and for detecting relapse in locally advanced cervical cancer
Presenter: Lars Sivars
Session: Poster session 11
809P - Mental and socioeconomic burden in endometrial and cervical cancer patients: A Swedish population-based study of survivorship
Presenter: jiangrong wang
Session: Poster session 11
810P - The influence of preoperative conization (pc) to patient’s (pts) outcome and tumor biology of cervical cancer (CC)
Presenter: Dimitra Trantaki
Session: Poster session 11
811P - Epidemiological landscape of cervical cancer in Latin America: EVITA LATAM (LACOG 0820)
Presenter: Graziela Zibetti Dal Molin
Session: Poster session 11